niclosamide has been researched along with Lung Diseases, Interstitial in 1 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niclosamide (Ncl) is an antihelminthic drug approved by FDA, which has been reported to have pleiotropic pharmacological activities in recent years, but it's almost complete insolubility in water limits its clinical application." | 1.91 | Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro. ( Gan, C; Gong, C; Liu, H; Ouyang, L; Tan, Z; Wang, Y; Xiang, Z; Xie, Y; Yao, Y; Ye, T, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gan, C | 1 |
| Wang, Y | 1 |
| Xiang, Z | 1 |
| Liu, H | 1 |
| Tan, Z | 1 |
| Xie, Y | 1 |
| Yao, Y | 1 |
| Ouyang, L | 1 |
| Gong, C | 1 |
| Ye, T | 1 |
1 other study available for niclosamide and Lung Diseases, Interstitial
| Article | Year |
|---|---|
Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro.
Topics: Alveolar Epithelial Cells; Animals; Extracellular Matrix; Idiopathic Pulmonary Fibrosis; Lung Diseas | 2023 |